Yet, the complete involvement of YAP in the development of drug tolerance and resistance, the mechanisms by which YAP activation occurs and can restrict therapy response in NSCLC, and the clinical validation of YAP activation in human tumor specimens remain to be fully elucidated. This evidence concerns the gene YAP1 and neoplasm.